Drug Information

Drug (ID: DG01664) and It's Reported Resistant Information

• Name: Cixutumumab
• Synonyms: SCHEMBL20511307
• Indication:
  In total 2 Indication(s)
  Liver cancer [ICD-11: 2C12]; Approved; [1]
  Non-small-cell lung cancer [ICD-11: 2C25]; Phase 2; [1]
• Target: Insulin-like growth factor I receptor (IGF1R); IGF1R_HUMAN; [1]
• Formula: 6
• IsoSMILES: CC#CC(=O)N1CCCC[C@H]1C2=NC(=C3N2C=CN=C3C(=O)O)C4=CC=C(C=C4)OC5=CC=CC(=C5F)OC
• InChI: InChI=1S/C29H25FN4O5/c1-3-7-23(35)33-16-5-4-8-20(33)28-32-25(27-26(29(36)37)31-15-17-34(27)28)18-11-13-19(14-12-18)39-22-10-6-9-21(38-2)24(22)30/h6,9-15,17,20H,4-5,8,16H2,1-2H3,(H,36,37)/t20-/m0/s1
• InChIKey: BPGVVRUPKNFLHW-FQEVSTJZSA-N
• PubChem CID: 135338442
• DrugBank ID: DB12250

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Ewing sarcoma [ICD-11: 2B52]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Protein-tyrosine phosphatase delta (PTPRD) [1]

• Molecule Alteration: Missense mutation; p.V253I (c.757G>A)
• Sensitive Disease: Ewing sarcoma [ICD-11: 2B52.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Ewing sarcoma tissue; N.A.
• Experiment for Molecule Alteration: DNA sequencing assay
• Mechanism Description: The missense mutation p.V253I (c.757G>A) in gene PTPRD cause the sensitivity of Cixutumumab by unusual activation of pro-survival pathway

References

• Ref 1: Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implicationsOncotarget. 2013 Jun;4(6):884-9. doi: 10.18632/oncotarget.1021.